USFDA okays Mylan, Biocon’s biosimilar of cancer drug Herceptin Industry-The Economic Times — December 2, 2017 comments off Ogivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the US.
Ogivri is the first USFDA approved biosimilar to Herceptin and the first biosimilar from Mylan and Biocon’s joint portfolio approved in the US.